细胞外容积分数MRI:作为动态对比增强MRI预测胰腺导管腺癌化疗反应的替代生物标志物
回顾性纳入58例经组织学确诊的胰腺导管腺癌患者,化疗前行动态对比增强MRI和平衡对比增强MRI测定细胞外容积分数;反应组肿瘤Ktrans、ve和细胞外容积分数均显著高于无反应组,细胞外容积分数预测化疗反应的AUC最高(0.918),与Ktrans和ve呈正相关;结论认为细胞外容积分数与DCE-MRI药代动力学参数预测化疗反应同样有用。
要点
- 细胞外容积分数预测胰腺导管腺癌化疗反应的AUC为0.918,敏感度89.3%、特异度90.0%、准确率89.7%,截断值>37.6%。
- 反应组肿瘤Ktrans、ve和细胞外容积分数均显著高于无反应组(均P<0.001),kep两组无显著差异(P=0.119)。
- 细胞外容积分数与Ktrans(Spearman系数=0.66)和ve(Spearman系数=0.79)呈显著正相关(均P<0.001)。
核心结论
- 平衡对比增强MRI测定的细胞外容积分数在预测胰腺导管腺癌化疗反应方面与DCE-MRI药代动力学参数同样有用。
研究设计与样本
- 回顾性研究,连续纳入58例经组织学确诊的胰腺导管腺癌患者,化疗前行DCE-MRI,比较反应组与无反应组的肿瘤药代动力学参数和细胞外容积分数。
诊断标准与关键数值
- 细胞外容积分数预测化疗反应的AUC为0.918,敏感度89.3%、特异度90.0%、准确率89.7%,截断值>37.6%;反应组肿瘤Ktrans、ve和细胞外容积分数均显著高于无反应组(均P<0.001),kep两组无显著差异(P=0.119)。
临床应用与阅片要点
- 细胞外容积分数与Ktrans(Spearman系数=0.66)和ve(Spearman系数=0.79)呈显著正相关(均P<0.001),可作为DCE-MRI药代动力学参数的替代预测指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the feasibility of extracellular volume (ECV) fraction determined with equilibrium contrast-enhanced MRI for prediction of treatment response to chemotherapy in pancreatic ductal adenocarcinoma (PDAC) in comparison with dynamic contrast-enhanced MRI (DCE-MRI), and to clarify the association between ECV fraction and DCE-MRI-derived pharmacokinetic parameters.
METHODS: This retrospective study included 58 consecutive patients with histologically confirmed PDAC who underwent DCE-MRI before systemic chemotherapy. Tumor pharmacokinetic parameters, including the volume transfer coefficient (Ktrans), rate constant (kep), and extracellular extravascular volume fraction (ve) of DCE-MRI, and ECV fraction determined with equilibrium contrast-enhanced MRI were compared between the response and non-response groups. The correlation of tumor ECV fraction with each DCE-MRI-derived pharmacokinetic parameter was examined using Spearman's rank correlation coefficient.
RESULTS: Tumor Ktrans, ve, and ECV fraction were significantly higher in the response group than in the non-response group (all, P < 0.001), whereas no significant difference was found in kep (P = 0.119). Tumor ECV fraction showed the highest area under receiver operating characteristic curve of 0.918, with a sensitivity of 89.3%, specificity of 90.0%, and accuracy of 89.7% (cut off, >37.6%). The ECV fraction showed a significant positive correlation with Ktrans (Spearman's coefficient = 0.66, P < 0.001) and ve (Spearman's coefficient = 0.79, P < 0.001).
CONCLUSIONS: ECV fraction determined with equilibrium contrast-enhanced MRI was as useful as DCE-MRI-derived pharmacokinetic parameters for predicting treatment response to chemotherapy in patients with PDAC.
引用
- Fukukura, Kumagae, Fujisaki, et al. Extracellular volume fraction with MRI: As an alternative predictive biomarker to dynamic contrast-enhanced MRI for chemotherapy response of pancreatic ductal adenocarcinoma. Eur J Radiol. 2021. PMID: 34814039. doi:10.1016/j.ejrad.2021.110036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。